MARK MELDEN: Open Payments
NPI 1982653135 · CORONADO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,500 in 115 payments from 19 companies in 2025. Trend: 2023 $997 · 2024 $1,259 · 2025 $2,500
Food & beverage: $2,388Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $380 |
| Neurocrine BioSciences, Inc. | 11 | $267 |
| Teva Pharmaceuticals USA, Inc. | 7 | $254 |
| Otsuka America Pharmaceutical, Inc. | 12 | $229 |
| E.R. Squibb & Sons, L.L.C. | 11 | $215 |
| Lundbeck LLC | 7 | $179 |
| Axsome Therapeutics, Inc. | 8 | $160 |
| Vanda Pharmaceuticals Inc. | 12 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $143 |
| Indivior Inc. | 4 | $106 |
Products named: VRAYLAR, REXULTI, INGREZZA, COBENFY, Auvelity, FANAPT, CAPLYTA, SUBLOCADE.
Industry payments across CA — which companies pay providers there.
